Ipsen (FR:IPN) has released an update.
Ipsen has expanded its agreement with Exelixis, leveraging promising results from the CABINET Phase III trial to potentially market Cabometyx® for advanced neuroendocrine tumors in territories excluding the U.S. and Japan. The trial showed a significant improvement in progression-free survival for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. Ipsen is now in discussions with EU regulatory authorities to pursue marketing authorizations based on these clinical findings.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.